• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now

    7/16/24 7:00:00 AM ET
    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Major Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASPI alert in real time by email

    MIAMI, July 16, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    [email protected]

    QuoteMedia.com

    ProCore Advisory - Unleashing the power of strategic investor relations for public and pre-IPO companies

    (832)-847-1327

    [email protected]

    www.procoreadvisory.com

    Day 1

    July 17, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    BlockchainK2 Corp. (OTCQB:BIDCF) (TSXV:BITK)

    Keynote speaker: Scott Brooks, CEO of RealBlocks

    9:40 - 10:10

    iQSTEL Inc. (OTCQX:IQST) 

    Keynote speaker: Leandro Jose Iglesias, Co-Founder, Chairman, President & CEO

    10:15 - 10:45

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    10:50 - 11:20

    Cyios Corp. (OTC:CYIO)

    Keynote speaker: John O'Shea, Chairman

    11:25 - 11:55

    22nd Century Group, Inc. (NASDAQ:XXII)

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    1:10 - 1:40

    Peninsula Energy Limited (OTCQB:PENMF) (ASX: PEN) 

    Keynote speaker: Wayne W. Heili, MD, CEO & Director

    1:45 - 2:15

    US Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, CEO

    2:20 – 2:30

    Big Screen Entertainment Group (OTC:BSEG)

    Keynote speakers: Monroe Mann, VP of Development of Big Film Fund

    2:50 – 3:00

    Intellabridge Technology Corporation (CSE:KASH) (OTCQB:KASHF) (FSE: KASH) 

    Keynote speaker: John Eagleton, CEO

    3:05 – 3:15

    LogicMark, Inc. (NASDAQ:LGMK)

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

    3:20 – 3:30

    Targa Exploration Corp. (CSE:TEX) (OTCQB:TRGEF)

    Keynote speaker: Cameron Tymstra, President & CEO

    3:35 – 3:45

    ReGen III Corp. (OTCQB:ISRJF) (TSXV:GIII)

    Keynote speaker: Mark Redcliffe, President

    Day 2

    July 18, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    Immuron Limited (ASX: IMC) (NASDAQ: IMRN

    Keynote speaker: Steve Lydeamore, CEO

    9:40 - 10:10

    CytoMed Therapeutics, Ltd. (NASDAQ: GDTC)

    Keynote speaker: Peter Choo, Chairman

    10:15 - 10:45

    Ethema Health Corporation (OTCQB:GRST)

    Keynote speaker: Shawn E. Leon – CEO

    10:50 – 11:20

    NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO)

    Keynote speaker: Hyung Heon Kim, Chief Executive Officer and President

    11:25 - 11:55

    Nascent Biotech, Inc. (OTCQB:NBIO)

    Keynote speaker: Sean Carrick, President / CEO

    12:00 – 12:30

    GeoVax Lags, Inc. (NASDAQ:GOVX)

    Keynote speaker: David Dodd, Chairman, President / CEO

    12:35 – 1:05

    Elutia, Inc. (NASDAQ:ELUT)

    Keynote speaker: Dr. Randy Mills, President & CEO

    1:10 – 1:40

    CervoMed, Inc. (NASDAQ:CRVO)

    Keynote speaker: Bill Elder, CFO & General Counsel

    1:45 – 2:15

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    2:20 – 2:50

    AseptiScope, Inc.

    Keynote speaker: Scott W Mader – Founder & CEO

    2:55 – 3:25

    NurExone Biologic Inc. (OTCQB:NRXBF) (TSXV:NRX)

    Keynote speaker: Dr. Lior Shaltiel – CEO

    3:30 – 3:40

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    3:45 – 3:55

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    4:00 – 4:10

    Ascend Wellness Holdings Inc. (OTCQX:AAWH)

    Keynote speaker: Keynote speaker: John Hartmann, CEO

    4:15 – 4:25

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    4:30 – 4:40

    Aytu BioPharma (NASDAQ:AYTU)

    Keynote speaker: Joshua Disbrow, Chairman, CEO

    4:45 – 4:55

    Clene Inc., (NASDAQ:CLNN)

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Brown, CFO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $ATRA
    $AYTU
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    CervoMed Inc.
    $CRVO
    12/18/2025Overweight
    Cantor Fitzgerald
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Aytu BioPharma Inc.
    $AYTU
    7/1/2025$8.00Buy
    Lake Street
    Aytu BioPharma Inc.
    $AYTU
    6/30/2025$12.00Buy
    Ascendiant Capital Markets
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    More analyst ratings

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:57 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wilcox Reed N

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:22 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mosca Alison

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:04:47 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on CervoMed

    Cantor Fitzgerald initiated coverage of CervoMed with a rating of Overweight

    12/18/25 9:09:07 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    SEC Filings

    View All

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    2/24/26 8:35:37 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    2/24/26 8:01:51 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    2/23/26 8:29:11 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shorepower Technologies (OTC: SPEV) Enters Merger Agreement with Aeternum Health LLC and Announces Strategic Transition to Longevity-Focused Healthcare Platform

    HILLSBORO, Ore., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shorepower Technologies, Inc. (OTC:SPEV) ("Shorepower" or the "Company") today announced that it has entered into an Agreement and Plan of Merger dated February 17, 2026, with Aeternum Health LLC ("Aeternum Health"), pursuant to which Aeternum Health will merge with and into Shorepower, with Shorepower continuing as the surviving entity.Upon completion of the merger, the Company intends to transition its strategic focus from transportation electrification infrastructure to the development of services, products, and solutions designed to increase longevity and optimize health outcomes. Transaction Summary Issuance of common stock represen

    2/24/26 8:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

    Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase 2 trial evaluating CAD-1005 (formerly VLX-1005) in patients with heparin-induced thrombocytopenia (HIT), a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant

    2/24/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

    Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated submission of a New Drug Application (NDA) to FDA for CNM-Au8 via an accelerated regulatory pathway in the second quarter of 2026Potential for FDA acceptance of this NDA and issuance of a Prescription Drug User Fee Act (PDUFA) date in the second half of 2026 SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical com

    2/24/26 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $AYTU
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care